Home > Resources > Whitepapers > Machine Learning, Artificial Intelligence, and Systems Biology: A New Way to Interrogate

Machine Learning, Artificial Intelligence, and Systems Biology: A New Way to Interrogate

December 1, 2016

Remarkable innovations in the technologies that generate ‘omics data have swiftly created such profound efficiencies that the cost of next-generation sequencing (NGS) has fallen below $1,000 per genome. This has led to the creation of vast amounts of data. The challenge of how to harness this rich information, and from it harvest practicable therapeutics, has been thrust to the forefront of advanced analytics.It is anticipated that in the upcoming decade genomics data will require more computing resources than the data demand from astronomy.

Spotlight

Metro North Hospital and Health Service

Metro North Hospital and Health Service (HHS) provides the full range of public sector health services including rural, regional and tertiary teaching hospitals. The HHS covers an area of 4157 square kilometres and extends from the Brisbane River to north of Kilcoy.

OTHER WHITEPAPERS

Impurity profiling and analysis of TheraPure GMP nucleotides

whitePaper | March 22, 2023

Nucleoside triphosphates (NTPs) are key building blocks of many nucleic acid therapeutics and vaccines. These molecules are a vital component of revolutionary new medicines.

Healthcare system readiness for the adoption of advanced therapies: learnings from the introduction of CAR T cell therapies in the UK

whitePaper | September 17, 2021

The adoption of CAR T therapies in the UK NHS is a success story, especially seen in relation to the experience in many other countries. The UK NHS showed itself to be agile, and responsive to addressing the unique challenges these therapies present, which facilitated access to patients earlier than in many other countries. (including delivery centre selection, development of service specifications, collaboration with manufacturers throughout the preparation phase for adoption, establishment of national multidisciplinary CAR T team to ensure equity of access and prioritization of resources (where needed)).

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).

Understanding Single-Pass Tangential Flow Filtration and the New Era of Bioprocessing

whitePaper | December 22, 2022

Single-pass tangential flow filtration (SPTFF) technology from Pall Corporation is revolutionizing current and future bioprocessing platforms with its implementations in biotech, vaccine and plasma industries. Its features are protected by a portfolio of patents[1-6].

Valorization of Starch to Biobased Materials

whitePaper | May 30, 2022

Many concerns are being expressed about the biodegradability, biocompatibility, and longterm viability of polymer-based substances. This prompted the quest for an alternative source of material that could be utilized for various purposes.

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.